The Brokerages Set Ironwood Pharmaceuticals Inc. (IRWD) PT at $15.56

The Brokerages Set Ironwood Pharmaceuticals Inc. (IRWD) PT at $15.56

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) has been assigned an average rating of “Hold” from the thirteen research firms that are covering the stock. One equities research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $15.56.

Several analysts have recently weighed in on the stock. WallachBeth Capital lifted their target price on shares of Ironwood Pharmaceuticals from $15.00 to $17.00 and gave the company a “hold” rating in a research report on Tuesday, September 27th. Wedbush restated a “neutral” rating and issued a $13.00 price target on shares of Ironwood Pharmaceuticals in a research report on Thursday, December 22nd. Mizuho restated a “buy” rating and issued a $21.00 price target (up from $20.00) on shares of Ironwood Pharmaceuticals in a research report on Friday, December 23rd. Zacks Investment Research upgraded shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, October 19th. Finally, BTIG Research restated a “buy” rating and issued a $18.00 price target (up from $15.00) on shares of Ironwood Pharmaceuticals in a research report on Friday, September 23rd.

In related news, Director Lawrence S. Olanoff sold 3,200 shares of the business’s stock in a transaction that occurred on Monday, December 5th. The shares were sold at an average price of $15.68, for a total transaction of $50,176.00. Following the completion of the sale, the director now directly owns 26,105 shares of the company’s stock, valued at $409,326.40. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Peter M. Hecht sold 65,987 shares of the business’s stock in a transaction that occurred on Thursday, January 12th. The stock was sold at an average price of $15.67, for a total transaction of $1,034,016.29. Following the sale, the chief executive officer now directly owns 4,703,315 shares of the company’s stock, valued at $73,700,946.05. The disclosure for this sale can be found here. Corporate insiders own 7.17% of the company’s stock.

Large investors have recently bought and sold shares of the company. Strs Ohio acquired a new stake in Ironwood Pharmaceuticals during the third quarter worth $107,000. Joel Isaacson & Co. LLC acquired a new stake in Ironwood Pharmaceuticals during the third quarter worth $109,000. Acrospire Investment Management LLC increased its stake in Ironwood Pharmaceuticals by 20.0% in the third quarter. Acrospire Investment Management LLC now owns 7,800 shares of the company’s stock worth $124,000 after buying an additional 1,300 shares during the period. SG Americas Securities LLC acquired a new stake in Ironwood Pharmaceuticals during the third quarter worth $127,000. Finally, BNP Paribas Arbitrage SA increased its stake in Ironwood Pharmaceuticals by 114.2% in the third quarter. BNP Paribas Arbitrage SA now owns 10,767 shares of the company’s stock worth $171,000 after buying an additional 5,741 shares during the period. 94.65% of the stock is owned by institutional investors and hedge funds.

Ironwood Pharmaceuticals (NASDAQ:IRWD) opened at 15.20 on Thursday. The firm’s market cap is $2.22 billion. The company’s 50 day moving average is $15.49 and its 200-day moving average is $14.61. Ironwood Pharmaceuticals has a 1-year low of $7.35 and a 1-year high of $16.89.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its earnings results on Thursday, November 3rd. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.05. Ironwood Pharmaceuticals had a negative net margin of 34.29% and a negative return on equity of 94.17%. The business had revenue of $66 million for the quarter, compared to analyst estimates of $60.01 million. During the same period in the previous year, the business earned ($0.25) EPS. The firm’s revenue was up 66.7% on a year-over-year basis. On average, analysts predict that Ironwood Pharmaceuticals will post ($0.75) EPS for the current fiscal year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company’s products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders.

Related posts

Leave a Comment